Financhill
Buy
57

FATE Quote, Financials, Valuation and Earnings

Last price:
$1.37
Seasonality move :
3.56%
Day range:
$1.33 - $1.40
52-week range:
$0.66 - $1.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.73x
P/B ratio:
0.68x
Volume:
1.3M
Avg. volume:
1.7M
1-year change:
-10.46%
Market cap:
$158M
Revenue:
$13.6M
EPS (TTM):
-$1.32

Fate Therapeutics, Inc. SEC Filings

Company Filed Form Type Description
FATE
Fate Therapeutics, Inc.
05/09/2024 10-Q 10-Q filing on 05/09/2024 View Form
FATE
Fate Therapeutics, Inc.
11/08/2023 10-Q 10-Q filing on 11/08/2023 View Form
FATE
Fate Therapeutics, Inc.
08/08/2023 10-Q 10-Q filing on 08/08/2023 View Form
FATE
Fate Therapeutics, Inc.
05/03/2023 10-Q 10-Q filing on 05/03/2023 View Form
FATE
Fate Therapeutics, Inc.
11/03/2022 10-Q 10-Q filing on 11/03/2022 View Form
FATE
Fate Therapeutics, Inc.
08/03/2022 10-Q 10-Q filing on 08/03/2022 View Form
FATE
Fate Therapeutics, Inc.
05/04/2022 10-Q 10-Q filing on 05/04/2022 View Form
FATE
Fate Therapeutics, Inc.
11/04/2021 10-Q 10-Q filing on 11/04/2021 View Form
FATE
Fate Therapeutics, Inc.
08/04/2021 10-Q 10-Q filing on 08/04/2021 View Form
FATE
Fate Therapeutics, Inc.
05/05/2021 10-Q 10-Q filing on 05/05/2021 View Form
FATE
Fate Therapeutics, Inc.
11/05/2020 10-Q 10-Q filing on 11/05/2020 View Form
FATE
Fate Therapeutics, Inc.
08/05/2020 10-Q 10-Q filing on 08/05/2020 View Form
FATE
Fate Therapeutics, Inc.
05/11/2020 10-Q 10-Q filing on 05/11/2020 View Form
FATE
Fate Therapeutics, Inc.
03/02/2020 10-K 10-K filing on 03/02/2020 View Form
FATE
Fate Therapeutics, Inc.
11/05/2019 10-Q 10-Q filing on 11/05/2019 View Form
FATE
Fate Therapeutics, Inc.
08/06/2019 10-Q 10-Q filing on 08/06/2019 View Form
FATE
Fate Therapeutics, Inc.
05/07/2019 10-Q 10-Q filing on 05/07/2019 View Form
FATE
Fate Therapeutics, Inc.
03/05/2019 10-K 10-K filing on 03/05/2019 View Form
FATE
Fate Therapeutics, Inc.
02/08/2019 10-Q 10-Q filing on 02/08/2019 View Form
FATE
Fate Therapeutics, Inc.
11/01/2018 10-Q 10-Q filing on 11/01/2018 View Form
FATE
Fate Therapeutics, Inc.
08/06/2018 10-Q 10-Q filing on 08/06/2018 View Form
FATE
Fate Therapeutics, Inc.
05/10/2018 10-Q 10-Q filing on 05/10/2018 View Form
FATE
Fate Therapeutics, Inc.
03/05/2018 10-K 10-K filing on 03/05/2018 View Form
FATE
Fate Therapeutics, Inc.
11/01/2017 10-Q 10-Q filing on 11/01/2017 View Form
FATE
Fate Therapeutics, Inc.
08/14/2017 10-Q 10-Q filing on 08/14/2017 View Form
FATE
Fate Therapeutics, Inc.
05/15/2017 10-Q 10-Q filing on 05/15/2017 View Form
FATE
Fate Therapeutics, Inc.
03/16/2017 10-K 10-K filing on 03/16/2017 View Form
FATE
Fate Therapeutics, Inc.
11/07/2016 10-Q 10-Q filing on 11/07/2016 View Form
FATE
Fate Therapeutics, Inc.
08/08/2016 10-Q 10-Q filing on 08/08/2016 View Form
FATE
Fate Therapeutics, Inc.
05/09/2016 10-Q 10-Q filing on 05/09/2016 View Form
FATE
Fate Therapeutics, Inc.
03/03/2016 10-K 10-K filing on 03/03/2016 View Form

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Celestica The Best AI Stock to Buy Now?
Is Celestica The Best AI Stock to Buy Now?

Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…

Will AI Disrupt SaaS Software Stocks?
Will AI Disrupt SaaS Software Stocks?

Since January 28th, software stocks in the United States have…

Why Is Meta Stock Going Higher?
Why Is Meta Stock Going Higher?

Over the last five days, shares of Instagram and Facebook…

Stock Ideas

Buy
56
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Sell
49
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 35x

Sell
44
Is GOOG Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 28x

Alerts

Buy
73
HYMC alert for Feb 19

Hycroft Mining Holding Corp. [HYMC] is up 21.1% over the past day.

Buy
90
TCMD alert for Feb 19

Tactile Systems Technology, Inc. [TCMD] is up 17.83% over the past day.

Buy
57
GLBE alert for Feb 19

Global-e Online Ltd. [GLBE] is up 17.31% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock